PRMT3 and lung carcinoma: In conclusion, these findings delineate PRMT3-mediated Kyn metabolism as a mechanism of radioresistance and immune evasion in non–small cell lung cancer, offering valuable insights for potential interventions for treating patients with lung cancer.